Skip to content
The Policy VaultThe Policy Vault

Mekinist (trametinib) — Medica

Solid Tumors

Initial criteria

  • Patient has BRAF V600 mutation-positive disease
  • The medication will be taken in combination with Tafinlar (dabrafenib)

Approval duration

1 year